NORAD and hepatocellular carcinoma: Apart from endometrial cancer in which up-regulation of NORAD determined good prognosis (Han et al., 2020), in other types of cancers, including cervical cancer (Huo et al., 2018), breast cancer (Zhou et al., 2019), bladder cancer (Li et al., 2018), esophageal cancer (Wu et al., 2017), gastric cancer (Yu et al., 2019), colorectal cancer (Zhang et al., 2018), pancreatic cancer (Li et al., 2017), hepatocellular carcinoma (Yang et al., 2019a), and lung cancer (Huang et al., 2020), its up-regulation was an indicator of poor survival.